AU2007235751A1 - Substituted ring fused azines and their use in cancer therapy - Google Patents

Substituted ring fused azines and their use in cancer therapy Download PDF

Info

Publication number
AU2007235751A1
AU2007235751A1 AU2007235751A AU2007235751A AU2007235751A1 AU 2007235751 A1 AU2007235751 A1 AU 2007235751A1 AU 2007235751 A AU2007235751 A AU 2007235751A AU 2007235751 A AU2007235751 A AU 2007235751A AU 2007235751 A1 AU2007235751 A1 AU 2007235751A1
Authority
AU
Australia
Prior art keywords
benzofuran
dimethyl
propanediamine
quinazolinyl
dihydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007235751A
Other languages
English (en)
Inventor
Bruce Charles Baguley
William Alexander Denny
Elaine Shirley Marshall
Hamish Scott Sutherland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of AU2007235751A1 publication Critical patent/AU2007235751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
AU2007235751A 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy Abandoned AU2007235751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ546477A NZ546477A (en) 2006-04-07 2006-04-07 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
NZ546477 2006-04-07
PCT/NZ2007/000077 WO2007117161A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy

Publications (1)

Publication Number Publication Date
AU2007235751A1 true AU2007235751A1 (en) 2007-10-18

Family

ID=38581368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007235751A Abandoned AU2007235751A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy

Country Status (8)

Country Link
US (1) US20090318479A1 (sv)
EP (1) EP2004637A4 (sv)
JP (1) JP2009533338A (sv)
CN (1) CN101460490A (sv)
AU (1) AU2007235751A1 (sv)
CA (1) CA2648323A1 (sv)
NZ (1) NZ546477A (sv)
WO (1) WO2007117161A1 (sv)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046207A1 (en) * 2010-10-08 2012-04-12 Paraco Technology Limited Anti-parasitic substituted ring fused azine compounds
US8710064B2 (en) * 2011-10-20 2014-04-29 China Medical University 2-aryl-4-quinazolinones and their pharmaceutical compositions
MX2014014832A (es) 2012-06-07 2015-02-12 Hoffmann La Roche Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
BR112014030410A2 (pt) 2012-06-07 2017-06-27 Hoffmann La Roche inibidores de pirazolopirimidona e pirazolopiridona de tanquirase
JP2016516691A (ja) 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのイソキノリン
JP6527513B2 (ja) 2013-11-20 2019-06-05 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのキナゾリン誘導体
SG11201702075QA (en) * 2014-10-29 2017-04-27 Dong A St Co Ltd Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
US20170057955A1 (en) * 2015-08-26 2017-03-02 Dong-A Socio Holdings Co., Ltd. Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs)
CN107721982B (zh) * 2017-10-16 2019-12-03 中山大学 一种抗肥胖症化合物及其制备方法和应用
CN110483394A (zh) * 2019-09-02 2019-11-22 广东工业大学 一种化合物的应用
CN113072543B (zh) * 2020-01-03 2022-07-22 南方医科大学 一种2-芳杂环基喹唑啉酮类化合物及其制备方法和用途
US20230339866A1 (en) * 2020-02-04 2023-10-26 TroBio Therapeutics Pty Ltd Quinazoline compounds and the use thereof in the treatment of cancer
AU2021342568A1 (en) 2020-09-21 2023-04-20 Landos Biopharma, Inc. Nlrx1 ligands
CN114044769B (zh) * 2021-11-25 2023-12-12 中山大学 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897432A (en) * 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
EE200100302A (et) * 1998-12-02 2002-08-15 Pfizer Products Inc. Meetodid ja kompositsioonid p53 perekonna valgu konformatsioonilise stabiilsuse taastamiseks
DK1088818T3 (da) * 1999-10-01 2005-03-14 Hoffmann La Roche Quinolin-4-yl-derivater
JP3649395B2 (ja) * 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
WO2002062767A1 (fr) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline

Also Published As

Publication number Publication date
EP2004637A1 (en) 2008-12-24
JP2009533338A (ja) 2009-09-17
US20090318479A1 (en) 2009-12-24
CA2648323A1 (en) 2007-10-18
CN101460490A (zh) 2009-06-17
EP2004637A4 (en) 2010-11-03
NZ546477A (en) 2009-04-30
WO2007117161A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
AU2007235751A1 (en) Substituted ring fused azines and their use in cancer therapy
JP6673920B2 (ja) Ｐａｒｇ阻害化合物
US9994529B2 (en) Amino quinazolines as kinase inhibitors
CA2700903C (en) Parp inhibitor compounds
JP4848286B2 (ja) 複素環アミド化合物及びｍｍｐ−１３阻害剤としてのその用途
Ohashi et al. Discovery of pyrrolo [3, 2-c] quinoline-4-one derivatives as novel hedgehog signaling inhibitors
WO2009084695A1 (ja) ２－アミノキナゾリン誘導体
CA2574685A1 (en) Quinazolin-4-yl- piperidine and cinnolin-4-yl- piperidine derivatives as pde10 inhibitors for the treatment of cns disorders
BRPI0618668B1 (pt) Compostos inibidores dos receptores de tirosina quinase do tipo i, composições compreendendo tais compostos, e seus usos
WO2009077956A2 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Нh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
AU2014249003A1 (en) Novel compounds and compositions for inhibition of FASN
WO2003055492A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
AU2013339167A1 (en) Novel amine derivative or salt thereof
JP2006520397A (ja) 新規融合トリアゾロン類及びその使用
Long et al. Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors
WO2003068754A1 (en) Therapeutic substituted indazole derivatives
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
He et al. New quinazoline derivatives for telomeric G-quadruplex DNA: Effects of an added phenyl group on quadruplex binding ability
EP1228043B1 (en) Isoquinoline and quinazoline deivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
WO2009003911A1 (en) Thiophene-imidazopyridines
US9643968B2 (en) Fused acridine derivative and pharmaceutical composition, preparation method and use thereof
CN114728963A (zh) 新型三唑吡啶衍生物和包括其的药物组合物
HAMMER et al. Patent 3007025 Summary

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application